Evidence on Mental Health
Here you'll find an up-to-date collection of our products in the area of mental health. These range from short reports to in-depth systematic reviews and various tools and resources geared to translating mental health research evidence into action.
We’ve selected the following materials to get you started:
- Nabilone for the Treatment of Post-Traumatic Stress Disorder: A 2023 Update (Health Technology Review, Feb 24, 2023)
- In Brief: Peer Support Programs for Youth Mental Health (Tool, November 10, 2022)
- Melatonin for the Treatment of Insomnia: A 2022 Update (Health Technology Review, May 2022)
- Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder (In Brief, May 2022)
- Cannabis for Opioid Use Disorder (Health Technology Review, October 2022)
- Artificial Intelligence in Mental Health Services: Results From a Literature Review and an Environmental Scan (Tool, August 16, 2021)
- In Brief: Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder (Optimal Use, January 2020)
In this Bundle
-
Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders
Evidence Highlights
-
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders
(Rapid Review, June 25, 2021)
-
Stellate Ganglion Block for the Treatment of Post-Traumatic Stress Disorder, Depression, and Anxiety
(Summary with Critical Appraisal, March 3, 2021)
-
Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment
Short on time? Read the In Brief.
-
Psychotherapy and Pharmacotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Rapid Qualitative Review
(Summary with Critical Appraisal, June 4, 2019)
-
Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders
Evidence Highlights
-
Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder
Short on time? Read the In Brief.
-
Pharmacogenomic Testing in Depression: A 2021 Update
(Rapid Review, January 18, 2022)
-
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders
(Rapid Review, June 25, 2021)
-
Bupropion for Major Depressive Disorder or Persistent Depressive Disorder (Dysthymia)
(Summary with Critical Appraisal, April 26, 2021)
-
Bupropion for Treatment Resistant Depression
(Summary with Critical Appraisal, April 12, 2021)
-
Stellate Ganglion Block for the Treatment of Post-Traumatic Stress Disorder, Depression, and Anxiety
(Summary with Critical Appraisal, March 3, 2021)
-
Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines
(Summary with Critical Appraisal, February 24, 2020)
-
Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines
(Summary with Critical Appraisal, February 18, 2020)
-
Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis
(Technology Review, February 18, 2020)
-
Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines
(Summary with Critical Appraisal, October 24, 2019)
-
Internet-Delivered Cognitive Behavioural Therapy for Major Depressive Disorder and Anxiety Disorders: A Health Technology Assessment
Short on time? Read the In Brief.
-
Repetitive Transcranial Magnetic Stimulation for Patients with Depression: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update
(Summary with Critical Appraisal, June 28, 2019)
-
Psychotherapy and Pharmacotherapy for Major Depressive Disorder and Generalized Anxiety Disorder: A Rapid Qualitative Review
(Summary with Critical Appraisal, June 4, 2019)
-
Ketamine for Pharmacological Management of Aggression and Agitation in Pre-Hospital Settings: A Review of Comparative Clinical Effectiveness, Safety and Guidelines
(Summary with Critical Appraisal, May 13, 2019)
-
Considerations of Access and Inclusion in Adolescent Eating Disorder Care: A Custom Rapid Report
(Technology Review, April 20, 2023)
-
Gender Affirming Therapy for Gender Dysphoria: A Rapid Qualitative Review
(Summary with Critical Appraisal, June 29, 2020)
-
Primary Care Initiated Gender-Affirming Therapy for Gender Dysphoria: A Review of Evidence Based Guidelines
(Summary with Critical Appraisal, May 1, 2020)
-
Hearing Aids and Dementia
(Emerging Health Technologies, July 6, 2023)
-
Understanding the Portrait of Dementia Care in Canada: A CADTH Panel of Experts
(Emerging Health Technologies, August 10, 2022)
-
Utilization of Cholinesterase Inhibitors for Alzheimer’s Disease in Canada
(Technology Review, June 13, 2022)
-
An Overview of New and Emerging Technologies for Early Diagnosis of Alzheimer Disease
(Emerging Health Technologies, May 16, 2022)
-
Dementia Concerns and Considerations: A CADTH Panel of People With Lived Experience
(Technology Review, April 1, 2022)
-
Neuromodulation Technologies for the Treatment of Alzheimer Disease
(Emerging Health Technologies, September 27, 2021)
-
Patient Navigation Programs for People With Dementia
(Summary with Critical Appraisal, February 24, 2021)
-
Dementia Villages
Short on time? Read the In Brief.
-
Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines
(Summary with Critical Appraisal, July 17, 2019)
-
Electroconvulsive Therapy for the Treatment of the Behavioural and Psychological Symptoms of Dementia: A Review of Clinical Effectiveness and Guidelines
(Summary with Critical Appraisal, May 22, 2019)
-
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder
(Rapid Review, July 27, 2022)
-
Emergency Care Follow-Up for Children and Adolescents With Suicide Attempts or Ideation
(Rapid Review, August 1, 2023)
-
Occupational Therapy for Mental Health Conditions and Substance Use Disorders
(Rapid Review, April 27, 2023)
-
Peer Support Programs for Youth Mental Health
(Health Technology Assessment, November 8, 2022)
-
Internet-Delivered Cognitive Behavioural Therapy in the Treatment of Chronic Non-Cancer Pain
(Optimal Use, October 3, 2022)
-
Melatonin for the Treatment or Prevention of Delirium
(Rapid Review, May 17, 2022)
-
Floatation Therapy for Mental Health Conditions
(Rapid Review, December 14, 2021)
-
Artificial Intelligence and Machine Learning in Mental Health Services: An Environmental Scan
(Environmental Scan, June 14, 2021)
-
Artificial Intelligence and Machine Learning in Mental Health Services: A Literature Review
(Rapid Review, June 14, 2021)
-
Canine and Equine Therapy for Mental Health: A Review of Clinical Effectiveness
(Rapid Review, August 30, 2019)
-
Dialectical Behaviour Therapy for People with Borderline Personality Disorder: A Rapid Qualitative Review
(Summary with Critical Appraisal, November 26, 2020)
-
An Overview of Pharmacogenomic Testing for Psychiatric Disorders
(Emerging Health Technologies, June 6, 2023)
-
Trace Amine-Associated Receptor 1 Agonists for Schizophrenia
(Emerging Health Technologies, July 15, 2022)
-
Clinical Effectiveness of Second Generation Injectable Antipsychotics
(Rapid Review, May 12, 2022)
-
Cognitive Remediation Therapy for People With Schizophrenia Spectrum Disorder: A Rapid Qualitative Review
(Rapid Review, November 22, 2021)
-
Antipsychotic Drugs or Benzodiazepines for Rapid Tranquilization in Mental Health Facilities or Emergency Department Settings
(Rapid Review, August 5, 2021)
-
Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines
(Summary with Critical Appraisal, February 18, 2020)
-
Health Technology Update - Issue 26
Article #3: A New Point-of-Care Device for Clozapine Monitoring
-
Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness
(Summary with Critical Appraisal, January 3, 2019)
-
Treatment Strategies for Sexual Dysfunction Associated With Psychotropic Medications
(Rapid Review, October 13, 2022)
-
At-Home Polysomnography Versus In-Clinic Polysomnography for Sleep Disorders
(Rapid Review, August 4, 2023)
-
Melatonin for the Treatment of Insomnia: A 2022 Update
(Rapid Review, May 24, 2022)
-
Evaluating Peer Support Programs for Youth Mental Health — Summary of an Environmental Scan
(Tools, November 17, 2022)
-
In Brief: Peer Support Programs for Youth Mental Health
(Tools, November 10, 2022)
-
Artificial Intelligence in Mental Health Services: A Summary of a Literature Review
This summary tool summarizes findings from a literature review that evaluated the published evidence on artificial intelligence (AI) for the prevention, diagnosis, and treatment of mental health illnesses. It also summarizes findings on the clinical effectiveness of AI applications, purpose of use, patient populations, primary users, and related evidence-based guidelines.
-
Artificial Intelligence in Mental Health Services: A Summary of an Environmental Scan
This summary tool summarizes findings from an Environmental Scan that explored the types of artificial intelligence (AI) emerging or currently in use in mental health. The summary also includes information on AI research and development initiatives (across Canada and internationally), and policy considerations for AI as they relate to mental health.
-
Artificial Intelligence in Mental Health Services: Results From a Literature Review and an Environmental Scan
(Tools, August 16, 2021)
-
Internet-Delivered Cognitive Behavioural Therapy (iCBT) Programs for Major Depression and Anxiety Disorders in Canada
A summary of key findings of CADTH reports assessing the available evidence on pharmacological, psychological and alternative options for the treatment of PTSD.
-
Alternative treatments for depression: Time-tested or too soon to know?
Hospital News Article
-
Addressing Psychological Trauma Due to the COVID-19 Pandemic: Can Technology Help in a Time of Acute Crisis?
This webinar is part of a series of CADTH events related to the COVID-19 pandemic. Recognizing that the pandemic is the source of psychological trauma for many individuals, the purpose of this webinar is aimed at discussing the role of technology in addressing psychological trauma during a time of limited access to face-to-face treatment. Findings of a CADTH evidence review on internet-delivered cognitive behavioural therapy (iCBT) for post-traumatic stress disorder (PTSD) were presented. Dr. Rima Styra, Associate Professor of Psychiatry at the University of Toronto, offered a clinician’s perspective on the impact of this pandemic on people’s mental health (particularly health care staff) and the role that iCBT can have in the treatment of PTSD. Louise Bradley, President and CEO of the Mental Health Commission of Canada provided perspectives on the adaptation of the mental health system during the COVID-19 pandemic and information on resources for individuals in distress.
-
Internet-Delivered Cognitive Behavioural Therapy: A Look Into the Evidence and Saskatchewan’s Online Therapy Unit
This webinar is aimed to improve understanding of the evidence on iCBT and its role in the treatment of major depression and anxiety disorders. Lee Bourgeault a Certified Clinical Counsellor with the Online Therapy Unit in Regina described how the Online Therapy Unit program works in Saskatchewan.
-
Using technology to link more patients with mental health services: Internet-Based Cognitive Behavioural Therapy
Resource April 30, 2020
-
Internet-Delivered Cognitive Behavioural Therapy: A Look Into the Evidence and Saskatchewan’s Online Therapy Unit - Cloned
This webinar is aimed to improve understanding of the evidence on iCBT and its role in the treatment of major depression and anxiety disorders. Lee Bourgeault a Certified Clinical Counsellor with the Online Therapy Unit in Regina described how the Online Therapy Unit program works in Saskatchewan.
-
Accessing Mental Health Outside of a Therapist’s Office: iCBT for Major Depression and Anxiety Disorders
On November 27, 2019, CADTH hosted a national Evidence to Action event to introduce evidence reviews led by CADTH and Health Quality Ontario and to discuss the use and implementation of internet-delivered cognitive behavioural therapy (iCBT) for major depression and anxiety disorders in Canada. In the event, Karilyn Xu (student at York University and iCBT user) , Dr. David Gratzer (Psychiatrist at the Centre for Addiction and Mental Health, and Associate Chief of the General Adult Psychiatry and Health Systems Division), Patrick Mitchell (Director of the Mental Health and Addictions Policy, Accountability and Provincial Partnership at the Ontario Ministry of Health), and Dr. Heather Hadjistavropoulos (Professor in the Department of Psychology at the University of Regina and Founder and Director of the Online Therapy Unit in Saskatchewan) shared their perspectives on using and implementing iCBT for these conditions in Canada.
-
Toolkit for e-Mental Health Implementation
A resource for mental health professionals interested in implementing e-mental health innovations, such as telehealth, apps, messaging services, and any Internet-based mental health technology in clinical practice. Developed by the Mental Health Commission of Canada in partnership with the Centre for Research in Family Health, IWK Health Centre, and in consultation with stakeholders